Dapagliflozin Tablet
Product Images NDC 27241-151

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 27241-151). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg (Dapagliflozin 10mg)

FDA Label Image

5mg (Dapagliflozin 5mg)

This package contains dapagliflozin 5mg tablets. The recommended dosage is available in the prescribing information. Store the tablets at 20°C to 25°C, with excursions permitted between 15°C and 30°C. The package is child-resistant. Keep out of reach of children. Do not use if the inner seal of the bottle is broken or missing. The tablets are marketed by Ajanta Pharma USA Inc. and made in India. This pack includes 30 tablets of Dapagliflozin. Dispense the accompanying Medication Guide to each patient.*

FDA Label Image

Figure2 (Dapagliflozin Figure2)

This is a description of a study showing the adjusted mean change from baseline HbA1c (%) values over a period of 24 weeks. The graphs represent data for subjects who completed the study without rescue and include information on Dapagliflozin, Metformin, and a combination therapy of Dapagliflozin 10 mg + Metformin. The left side graph displays adjusted mean change values based on a longitudinal repeated measures model. The right side graph shows adjusted mean change values for Week 24 along with 95% confidence intervals based on an ANCOVA model.*

FDA Label Image

Figure3 (Dapagliflozin Figure3)

This text provides data on the adjusted mean change from baseline HbA1c levels for subjects in a study comparing a placebo plus metformin group to a group receiving dapagliflozin 10 mg plus metformin. The text includes information on study week, values for adjusted mean change from baseline based on a longitudinal repeated measures model, and 95% confidence intervals. The data refers to subjects who completed a Short-Term Period with both baseline and Week 24 HbA1c values without requiring rescue.*

FDA Label Image

Figure4 (Dapagliflozin Figure4)

FDA Label Image

Figure5 (Dapagliflozin Figure5)

FDA Label Image

Figure1 (Dapagliflozin Fig1)

Not available.*

FDA Label Image

Structure (Dapagliflozin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.